Boosting Drug Discovery for Parkinson’s: Enhancement of the Delivery of a Monoamine Oxidase-B Inhibitor by Brain-Targeted PEGylated Polycaprolactone-Based Nanoparticles

The current pharmacological treatments for Parkinson’s disease only offer symptomatic relief to the patients and are based on the administration of levodopa and catechol-O-methyltransferase or monoamine oxidase-B inhibitors (IMAO-B). Since the majority of drug candidates fail in pre- and clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinto, Miguel, Fernandes, Carlos, Martins, Eva, Silva, Renata, Benfeito, Sofia, Cagide, Fernando, Mendes, Ricardo F., Almeida Paz, Filipe A., Garrido, Jorge, Remião, Fernando, Borges, Fernanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681091/
https://www.ncbi.nlm.nih.gov/pubmed/31336891
http://dx.doi.org/10.3390/pharmaceutics11070331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681091/
https://www.ncbi.nlm.nih.gov/pubmed/31336891
http://dx.doi.org/10.3390/pharmaceutics11070331

Ejemplares similares